Review



cd34 multisort kit  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Miltenyi Biotec cd34 multisort kit
    Cd34 Multisort Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 95 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+cd34+multisort+kit/CD34+MultiSort+Kit%2C+human/pmc12408697-57-22-27
    Average 93 stars, based on 95 article reviews
    cd34 multisort kit - by Bioz Stars, 2026-11
    93/100 stars

    Images

    Related Articles

    Isolation:

    Article Title: Ginsenoside Rg1 promotes fetal hemoglobin production in vitro: A potential therapeutic avenue for β-thalassemia.
    Article Snippet: This mixture was then subjected to a density gradient centrifugation process using LymphoprepTM (STEMCELL Technologies, Canada), Centrifuge the mixture at 800×g for 30 min at room temperature to separate the mononuclear cell fraction. .. The isolation and purification of CD34+ cells from the mononuclear cell fraction were meticulously executed using the human CD34 MultiSort Kit (Miltenyi Biotec, Germany) (Farahzadi et al., 2023). ..

    Article Title: Cell type differences in activity of the Streptomyces bacteriophage ϕC31 integrase
    Article Snippet: .. CD34 + cells were further isolated from the initially separated MNC by high-gradient magnetic sorting using Human CD34 MultiSort Kit (MACS, Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) following manufacturer's protocol. .. A549 (alveolar type II cells), HepG2 (hepatocytes), HeLa (epithelial cervix carcinoma cells) and Jurkat (T cells) cell lines were obtained from German Collection of Microorganisms and Cell Cultures (DSMZ - Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany).

    Article Title: Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia
    Article Snippet: .. CD34+ BM-MNCs were isolated using the human CD34 MultiSort Kit (Miltenyi Biotec) following the manufacturer's instructions. .. Briefly, BM-MNCs were washed twice with MACS buffer (PBS containing 0.5% bovine serum albumin (BSA) and 2 mM EDTA), passed through a nylon mesh to remove cell clumps and incubated in MACS buffer supplemented with FcR Blocking Reagent and CD34 MultiSort MicroBeads for 30 min at 4°C.

    Purification:

    Article Title: Ginsenoside Rg1 promotes fetal hemoglobin production in vitro: A potential therapeutic avenue for β-thalassemia.
    Article Snippet: This mixture was then subjected to a density gradient centrifugation process using LymphoprepTM (STEMCELL Technologies, Canada), Centrifuge the mixture at 800×g for 30 min at room temperature to separate the mononuclear cell fraction. .. The isolation and purification of CD34+ cells from the mononuclear cell fraction were meticulously executed using the human CD34 MultiSort Kit (Miltenyi Biotec, Germany) (Farahzadi et al., 2023). ..

    Magnetic Cell Separation:

    Article Title: Cell type differences in activity of the Streptomyces bacteriophage ϕC31 integrase
    Article Snippet: .. CD34 + cells were further isolated from the initially separated MNC by high-gradient magnetic sorting using Human CD34 MultiSort Kit (MACS, Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) following manufacturer's protocol. .. A549 (alveolar type II cells), HepG2 (hepatocytes), HeLa (epithelial cervix carcinoma cells) and Jurkat (T cells) cell lines were obtained from German Collection of Microorganisms and Cell Cultures (DSMZ - Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany).

    Article Title: Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells
    Article Snippet: Prior to use in cytolysis experiments, the cells were thawed and cultured overnight in RPMI medium containing 5% human serum (Invitrogen) plus 50 units/ml and 50 μg/ml PS, respectively, but no additional IL-2. .. Enrichment of human CD34-positive cells by preparative sorting with immuno-magnetic beads CD34-positive cells were enriched by positive selection using the commercial human CD34+ Multisort Kit (Miltenyi Biotec MACS sorting kit, cat. #130–058-701) according to manufacturer’s instructions. ..

    Article Title: Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells
    Article Snippet: Prior to use in cytolysis experiments, the cells were thawed and cultured overnight in RPMI medium containing 5% human serum (Invitrogen) plus 50 units/ml and 50 μg/ml PS, respectively, but no additional IL-2. .. CD34-positive cells were enriched by positive selection using the commercial human CD34 + Multisort Kit (Miltenyi Biotec MACS sorting kit, cat. #130–058-701) according to manufacturer’s instructions. .. The fractions of CD33- and for some samples of CD123-expressing leukocytes were determined by FACS analysis (FACS Navios, Beckman Coulter).

    Selection:

    Article Title: Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells
    Article Snippet: Prior to use in cytolysis experiments, the cells were thawed and cultured overnight in RPMI medium containing 5% human serum (Invitrogen) plus 50 units/ml and 50 μg/ml PS, respectively, but no additional IL-2. .. Enrichment of human CD34-positive cells by preparative sorting with immuno-magnetic beads CD34-positive cells were enriched by positive selection using the commercial human CD34+ Multisort Kit (Miltenyi Biotec MACS sorting kit, cat. #130–058-701) according to manufacturer’s instructions. ..

    Article Title: Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells
    Article Snippet: Prior to use in cytolysis experiments, the cells were thawed and cultured overnight in RPMI medium containing 5% human serum (Invitrogen) plus 50 units/ml and 50 μg/ml PS, respectively, but no additional IL-2. .. CD34-positive cells were enriched by positive selection using the commercial human CD34 + Multisort Kit (Miltenyi Biotec MACS sorting kit, cat. #130–058-701) according to manufacturer’s instructions. .. The fractions of CD33- and for some samples of CD123-expressing leukocytes were determined by FACS analysis (FACS Navios, Beckman Coulter).

    Labeling:

    Article Title: A probable role for trail-induced apoptosis in the pathogenesis of marrow failure. Implications from an in vitro model and from marrow of aplastic anemia patients.
    Article Snippet: Aplastic anemia (AA) is a syndrome of hematopoietic failure involving increased apoptosis of stem cells.. In order to investigate the molecular mechanisms participated in the process of marrow failure, we created an in vitro model of hematopoietic cell suppression, by continuous addition of TNFand IFNin an vitro long-term bone marrow culture system.. An up-regulation of Fas expression was observed in CD34+ cells in cytokine treated cultures, compared to controls.

    Staining:

    Article Title: A probable role for trail-induced apoptosis in the pathogenesis of marrow failure. Implications from an in vitro model and from marrow of aplastic anemia patients.
    Article Snippet: Aplastic anemia (AA) is a syndrome of hematopoietic failure involving increased apoptosis of stem cells.. In order to investigate the molecular mechanisms participated in the process of marrow failure, we created an in vitro model of hematopoietic cell suppression, by continuous addition of TNFand IFNin an vitro long-term bone marrow culture system.. An up-regulation of Fas expression was observed in CD34+ cells in cytokine treated cultures, compared to controls.

    Incubation:

    Article Title: A probable role for trail-induced apoptosis in the pathogenesis of marrow failure. Implications from an in vitro model and from marrow of aplastic anemia patients.
    Article Snippet: Aplastic anemia (AA) is a syndrome of hematopoietic failure involving increased apoptosis of stem cells.. In order to investigate the molecular mechanisms participated in the process of marrow failure, we created an in vitro model of hematopoietic cell suppression, by continuous addition of TNFand IFNin an vitro long-term bone marrow culture system.. An up-regulation of Fas expression was observed in CD34+ cells in cytokine treated cultures, compared to controls.



    Similar Products

    93
    Miltenyi Biotec cd34 multisort kit
    Cd34 Multisort Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+cd34+multisort+kit/CD34+MultiSort+Kit%2C+human/pmc12408697-57-22-27
    Average 93 stars, based on 1 article reviews
    cd34 multisort kit - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    93
    Miltenyi Biotec human cd34 multisort kit
    Human Cd34 Multisort Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+cd34+multisort+kit/CD34+MultiSort+Kit%2C+human/pm38382804-65-17-21
    Average 93 stars, based on 1 article reviews
    human cd34 multisort kit - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    93
    Miltenyi Biotec human cd34 multisort
    Figure 2. Comparative immunopeptidome profiling identifies AML/LSC-associated HLA class I antigen targets. A, Saturation analysis of HLA class I-restricted peptide source proteins of the AML cohort. The mean number of unique source proteins (y-axis) for a given cohort size (number of samples, x-axis) has been calculated by 1,000 random samplings from the entirety of AML immunopeptidomes. The number of unique source protein identifica- tions (y-axis) is shown as a function of cumulative immunopeptidome analysis of AML samples (n = 47, x-axis). Exponential regression was used to extrapolate the maximum attainable coverage of different source proteins (dotted line, 11,193 proteins). The dashed line depicts the HLA-restricted peptide source proteome coverage achieved in the AML cohort (10,906 proteins). B, HLA class I allotype population coverage within the AML cohort com- pared with the world population (www.iedb.org). The frequencies of individuals within the world population carrying up to six HLA allotypes (x-axis) of the AML dataset are indicated as gray bars on the left y-axis. The cumulative percentage of population coverage is depicted as black dots on the right y-axis. C, Overlap analysis of HLA class I ligand identifications of primary AML samples (n = 47, curated immunopeptidome data) and benign samples (n = 332). D, Allotype-specific comparative immunopeptidome profiling based on the frequency of HLA-A*01–restricted peptide presentation in HLA-A*01–posi- tive AML (n = 14) and benign samples (n = 93). Frequencies of positive immunopeptidomes for the respective HLA ligand (x-axis) are indicated on the y-axis. HLA-A*01 ligands (n = 7,346) are depicted on the x-axis, sorted according to the frequency of AML and benign samples presenting the respective ligand. The box on the left highlights the subset of AML-associated antigens showing AML-exclusive, high frequent presentation. E, Overlap analysis of HLA class I ligand identifications of LSC samples (n = 10) with AML bulk (n = 47) and benign samples including <t>CD34+-enriched</t> HSPCs (n = 332). F, Pro- portion of all HLA class I and of HLA class I allotype-specific high frequent AML-associated peptides that are also presented on LSCs (AML/LSC shared antigens). N indicates the number of peptides. Abbreviations: ID, identification; IPep, immunopeptidome.
    Human Cd34 Multisort, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+cd34+multisort+kit/CD34+MultiSort+Kit%2C+human/10__1158_slash_2643___3230__bcd___23___0020-254-5-8
    Average 93 stars, based on 1 article reviews
    human cd34 multisort - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    93
    Miltenyi Biotec miltenyi cd34 multisort kit
    Figure 2. Comparative immunopeptidome profiling identifies AML/LSC-associated HLA class I antigen targets. A, Saturation analysis of HLA class I-restricted peptide source proteins of the AML cohort. The mean number of unique source proteins (y-axis) for a given cohort size (number of samples, x-axis) has been calculated by 1,000 random samplings from the entirety of AML immunopeptidomes. The number of unique source protein identifica- tions (y-axis) is shown as a function of cumulative immunopeptidome analysis of AML samples (n = 47, x-axis). Exponential regression was used to extrapolate the maximum attainable coverage of different source proteins (dotted line, 11,193 proteins). The dashed line depicts the HLA-restricted peptide source proteome coverage achieved in the AML cohort (10,906 proteins). B, HLA class I allotype population coverage within the AML cohort com- pared with the world population (www.iedb.org). The frequencies of individuals within the world population carrying up to six HLA allotypes (x-axis) of the AML dataset are indicated as gray bars on the left y-axis. The cumulative percentage of population coverage is depicted as black dots on the right y-axis. C, Overlap analysis of HLA class I ligand identifications of primary AML samples (n = 47, curated immunopeptidome data) and benign samples (n = 332). D, Allotype-specific comparative immunopeptidome profiling based on the frequency of HLA-A*01–restricted peptide presentation in HLA-A*01–posi- tive AML (n = 14) and benign samples (n = 93). Frequencies of positive immunopeptidomes for the respective HLA ligand (x-axis) are indicated on the y-axis. HLA-A*01 ligands (n = 7,346) are depicted on the x-axis, sorted according to the frequency of AML and benign samples presenting the respective ligand. The box on the left highlights the subset of AML-associated antigens showing AML-exclusive, high frequent presentation. E, Overlap analysis of HLA class I ligand identifications of LSC samples (n = 10) with AML bulk (n = 47) and benign samples including <t>CD34+-enriched</t> HSPCs (n = 332). F, Pro- portion of all HLA class I and of HLA class I allotype-specific high frequent AML-associated peptides that are also presented on LSCs (AML/LSC shared antigens). N indicates the number of peptides. Abbreviations: ID, identification; IPep, immunopeptidome.
    Miltenyi Cd34 Multisort Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+cd34+multisort+kit/CD34+MultiSort+Kit%2C+human/pm37761914-129-31-35
    Average 93 stars, based on 1 article reviews
    miltenyi cd34 multisort kit - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    Image Search Results


    Figure 2. Comparative immunopeptidome profiling identifies AML/LSC-associated HLA class I antigen targets. A, Saturation analysis of HLA class I-restricted peptide source proteins of the AML cohort. The mean number of unique source proteins (y-axis) for a given cohort size (number of samples, x-axis) has been calculated by 1,000 random samplings from the entirety of AML immunopeptidomes. The number of unique source protein identifica- tions (y-axis) is shown as a function of cumulative immunopeptidome analysis of AML samples (n = 47, x-axis). Exponential regression was used to extrapolate the maximum attainable coverage of different source proteins (dotted line, 11,193 proteins). The dashed line depicts the HLA-restricted peptide source proteome coverage achieved in the AML cohort (10,906 proteins). B, HLA class I allotype population coverage within the AML cohort com- pared with the world population (www.iedb.org). The frequencies of individuals within the world population carrying up to six HLA allotypes (x-axis) of the AML dataset are indicated as gray bars on the left y-axis. The cumulative percentage of population coverage is depicted as black dots on the right y-axis. C, Overlap analysis of HLA class I ligand identifications of primary AML samples (n = 47, curated immunopeptidome data) and benign samples (n = 332). D, Allotype-specific comparative immunopeptidome profiling based on the frequency of HLA-A*01–restricted peptide presentation in HLA-A*01–posi- tive AML (n = 14) and benign samples (n = 93). Frequencies of positive immunopeptidomes for the respective HLA ligand (x-axis) are indicated on the y-axis. HLA-A*01 ligands (n = 7,346) are depicted on the x-axis, sorted according to the frequency of AML and benign samples presenting the respective ligand. The box on the left highlights the subset of AML-associated antigens showing AML-exclusive, high frequent presentation. E, Overlap analysis of HLA class I ligand identifications of LSC samples (n = 10) with AML bulk (n = 47) and benign samples including CD34+-enriched HSPCs (n = 332). F, Pro- portion of all HLA class I and of HLA class I allotype-specific high frequent AML-associated peptides that are also presented on LSCs (AML/LSC shared antigens). N indicates the number of peptides. Abbreviations: ID, identification; IPep, immunopeptidome.

    Journal: Blood Cancer Discovery

    Article Title: Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells

    doi: 10.1158/2643-3230.bcd-23-0020

    Figure Lengend Snippet: Figure 2. Comparative immunopeptidome profiling identifies AML/LSC-associated HLA class I antigen targets. A, Saturation analysis of HLA class I-restricted peptide source proteins of the AML cohort. The mean number of unique source proteins (y-axis) for a given cohort size (number of samples, x-axis) has been calculated by 1,000 random samplings from the entirety of AML immunopeptidomes. The number of unique source protein identifica- tions (y-axis) is shown as a function of cumulative immunopeptidome analysis of AML samples (n = 47, x-axis). Exponential regression was used to extrapolate the maximum attainable coverage of different source proteins (dotted line, 11,193 proteins). The dashed line depicts the HLA-restricted peptide source proteome coverage achieved in the AML cohort (10,906 proteins). B, HLA class I allotype population coverage within the AML cohort com- pared with the world population (www.iedb.org). The frequencies of individuals within the world population carrying up to six HLA allotypes (x-axis) of the AML dataset are indicated as gray bars on the left y-axis. The cumulative percentage of population coverage is depicted as black dots on the right y-axis. C, Overlap analysis of HLA class I ligand identifications of primary AML samples (n = 47, curated immunopeptidome data) and benign samples (n = 332). D, Allotype-specific comparative immunopeptidome profiling based on the frequency of HLA-A*01–restricted peptide presentation in HLA-A*01–posi- tive AML (n = 14) and benign samples (n = 93). Frequencies of positive immunopeptidomes for the respective HLA ligand (x-axis) are indicated on the y-axis. HLA-A*01 ligands (n = 7,346) are depicted on the x-axis, sorted according to the frequency of AML and benign samples presenting the respective ligand. The box on the left highlights the subset of AML-associated antigens showing AML-exclusive, high frequent presentation. E, Overlap analysis of HLA class I ligand identifications of LSC samples (n = 10) with AML bulk (n = 47) and benign samples including CD34+-enriched HSPCs (n = 332). F, Pro- portion of all HLA class I and of HLA class I allotype-specific high frequent AML-associated peptides that are also presented on LSCs (AML/LSC shared antigens). N indicates the number of peptides. Abbreviations: ID, identification; IPep, immunopeptidome.

    Article Snippet: MACS was performed with the human CD34 MultiSort (Miltenyi Biotec, catalog no. 130–056–701) and CD38 MicroBead Kits (Miltenyi Biotec, catalog no. 130–092–263).

    Techniques: